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ABSTRACT
Coronavirus disease 2019 (COVID-19) has already stated as a pandemic by 
the World Health Organization (WHO). Until now, Indonesia has also infected 
with this severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infections. All medical staffs join hand by hand to overcome this pandemic, 
not only pulmonologist but also cardiologist. Early reports from China showed 
that cardiovascular comorbidities add more mortality than without comorbid. 
Cardiac implication of this infection is cardiac injury. Viral pathology and 
pathophysiology that induced cardiac injury is still debatable and not well 
understood. Angiotensin-converting enzyme 2 (ACE2) has emerged as a key 
regulator of renin-angiotensin system in cardiovascular disease. ACE2 has 
been postulated as one of the pathophysiology of COVID-19 and cardiac injury.
ABSTRAK
Coronavirus disease 2019(COVID-19) telah dinyatakan sebagai pandemi oleh 
Organisasi Kesehatan Dunia (WHO). Saat ini, Indonesia juga telah terinfeksi 
dengan infeksi coronavirus 2 (SARS-CoV-2) yang parah. Semua staf medis 
bergandengan tangan untuk mengatasi pandemi ini, tidak hanya dokter 
paru tetapi juga ahli jantung. Laporan awal dari Cina menunjukkan bahwa 
komorbiditas kardiovaskular menambah lebih banyak kematian daripada 
tanpa komorbiditas. Implikasi jantung dari infeksi ini adalah cedera jantung. 
Patologi virus dan patofisiologi yang menyebabkan cedera jantung masih 
bisa diperdebatkan dan tidak dipahami dengan baik. Angiotensin-converting 
enzyme 2 (ACE2) telah muncul sebagai pengatur utama sistem renin-
angiotensin pada penyakit kardiovaskular. ACE2 telah disimpulkan sebagai 
salah satu patofisiologi COVID-19 dan cedera jantung.
INTRODUCTION
Coronavirus disease 2019 
(COVID-19) is a newly recognized viral 
infectious disease that has spread 
rapidly throughout Wuhan, Hubei, 
China, and several countries around 
the world, including Indonesia.1 Studies 
from China have described the clinical 
characteristics and findings of patients 
with severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2).2 Patient of 
COVID-19 showed respiratory symptoms 
but often has cardiovascular-related 
symptoms.3
The COVID-19 can cause cardiac 
injury and chronic damage to the 
cardiovascular system.3,4  The mechanism 
of myocardial injury caused by SARS-
CoV-2 infection might be related to 
angiotensin converting enzyme 2 
(ACE2).3 Chronic cardiovascular disease 
may become unstable because of this 
viral infection due to cytokine storm.3-5 
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Most of cardiac markers are high due to 
acute inflammation of COVID-19.6 The 
present review is focused on the role of 
ACE2 to cardiac injury in COVID-19.
COVID-19, ACE2 AND CARDIAC INJURY
Currently, our knowledge about 
SARS-CoV-2 as novel enveloped single-
stranded RNA beta-coronavirus(+ssRNA) 
is lacking, but it has phylogenetic 
similarity with severe acute respiratory 
syndrome corona virus (SARS-CoV) 
and middle east respiratory syndrome 
corona virus (MERS-CoV).7 Coronavirus 
are positive-single-stranded RNA that 
classified into four categories; alpha 
coronavirus (alphaCov), beta coronavirus 
(betaCoV), delta coronavirus (deltaCoV), 
and gamma coronavirus (gammaCoV).8 
RNA virus is a highly mutated, but 
exploring and defining their biological 
characters are less important than 
detection, contamination, treatment 
and analysis of viruses that are 
pathogenic to human succeeding their 
discovery.9 Even-though SARS-CoV-2 
is not a descendent of the SARS-CoV, 
but genetically both of them have 82% 
similarity in nucleotide identity.10 For 
that reason, the evolutionary history 
and characteristics of both viruses are 
conjointly informative in management 
of the current COVID-19 pandemic 
situation.
Based on previous insight about SARS 
and MERS, SARS-CoV-2 pathogenicity 
isdetermined by combination of viruses’ 
replication and host immune response. 
They have unique coding strategy by 
translated into two large polyproteins 
from viral RNA and exoribonuclease 
(ExonN) function which allow them to 
maintain a large RNA genome without the 
accumulation of lethal mutation.11 The 
SARS-CoV’s envelope spike glycoprotein 
binds with its cellular receptor, ACE2, and 
the MERS-CoV with dipeptidyl peptidase 
4 (DPP4).10,11 Since spike structure of 
SARS-CoV-2 more likely similar to SARS-
CoV, their spike hypotheses bind with 
ACE2 in human cellular, instead of with 
DPP4. SARS-CoV-2 is able to use all ACE2 
proteins to enter cells, but not cells that 
did not express ACE2, indicating that 
ACE2 is probably the cell receptor.12
Down regulation of the ACE2 is 
caused by attachment to SARS-CoV-2’s 
protein spike. Contrary, ACE2 also has 
a protective effect on heart and lung 
organs. During COVID-19 infection, the 
reduction of ACE2 means an increase 
in viral infection and deteriorating 
cardiac protective condition.11,13 Those 
condition makes angiotensin II (Ang II) 
increase and bind to angiotensin II type 
1 receptor (AT1R) which responsible in 
heart pathologic condition13. ACE2 will 
change Ang II into angiotensin1-7 (Ang1-
7) which responsible for opposing the 
proliferative and pro-fibrotic action of 
Ang II and acting via its own receptor. 
Binding of Ang1-7 and MasR willoppose 
the molecular and cellular effects of 
Ang II, such as antiatrophy, antifibrosis, 
antiinflammation, antioxidant and 
vasodilation.14,15
Secondly, like ACE2, immune 
response is important for resolution 
process especially in viral infection 
but at some point, it can be 
immunopathogenic condition. There 
is a possibility of recurrent symptoms 
after COVID-19 patient fully recovered 
despite the diminution of the viral 
load. The Immunopathologic condition 
might responsible for exacerbation of 
clinical condition within 3 weeks after 
recovered and threaten cardiovascular 
system independently with viral 
load.16,17 Retrospective longitudinal 
study shows fully recovered patient 
tends to develop an adaptive immune 
response and it suggests recurrent 
symptom might happen because failure 
to switch between innate to adaptive 
immune response.18 COVID-19-induced 
myocardial inflammation is mediated 
predominantly by macrophages and the 
resultant production of chemokines.19
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SARS-CoV-2 binds to ACE2 and 
involves cell surface associated 
trans-membrane protein serine 2 
(TMPRSS2)20in endothelial cell and 
presumably activatesa disintegrin and 
metalloprotease- 17 (ADAM17)21 or 
tumor necrosis factor alpha converting 
enzyme (TACE) by its protein spike and 
subsequent intracellular degradation of 
ACE2 or soluble ACE2 (sACE2). ADAM17/
TACE is a membrane-anchored protein 
responsible for ectodomain shedding 
of various trans-membrane proteins 
and it can initiation/ inhibition of signal 
cascade and cellular responses. TACE 
substrates are responsible for endothelial 
wall inflammation, atherosclerosis, and 
plaque formation and/or progression. 
The increasing local TACE activation 
correlates with macrophage infiltration 
and arterial remodeling. TACE, through 
up-regulation of tumor necrosis factor 
alpha (TNFα), promotes premature 
endothelial cell senescence and takes 
part in coronary artery aging process.22 
Degradation of ACE2 in endothelial 
cell worsening the situation and it 
can lead to endothelial dysfunction, 
vascular vasoconstriction, inflammatory 
response until promoting atherosclerotic 
evolution.23 FIGURE 1 explains the 
pathomechanism of COVID-19, ACE2, 
and cardiac injury.
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FIGURE 1. Pathomechanism of COVID-19, ACE2 and cardiac injury. ACE: 
Angiotensin Converting Enzyme; ACE2: Angiotensin Converting 
Enzyme 2; ADAM: A Disintegrin and Metalloprotease-17;Ang 1-7: 
Angiotensin 1-7; Ang 1-9: Angiotensin 1-9; AT1R: Angiotensin 
II type 1 Receptor; AT2R: Angiotensin II type 2 Receptor; MasR: 
Mas Receptor; SARS-CoV-2: Severe Acute Respiratory Syndrome 
CoronaVirus 2; sACE2: soluble Angiotensin Converting Emzyme 2; 
TACE: Tumor necrosis factor Alpha Converting Enzyme; TMPRSS2: 
Transmembrane protein serine 2.
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It has been proposed that treatment 
of hypertension with renin-angiotensin 
system (RAS) inhibitors may influence 
SARS-CoV-2 binding to ACE2, promoting 
the progress of COVID-19.24 RAS 
inhibitors cause a compensatory increase 
in tissue levels of ACE225 and may be 
detrimental in patients exposed to 
SARS-CoV-2.26 There is no clear evidence 
and association that using angiotensin-
converting enzyme inhibitors (ACEI) or 
angiotensin receptor blockers (ARB) lead 
to up-regulation and circulating levels of 
ACE2 in human tissues.27 Because of that 
reasons, no clinical evidence to support 
the effects of RAS inhibitors in COVID-19 
patients and also guidelines from major 
cardiovascular societies stated that 
patients on ACEI or ARB should not stop 
their medications.27,28
CONCLUSION
SARS-CoV-2 is thought to infect host 
cells through ACE2 to cause COVID-19, 
while also causing cardiac injury, 
although the specific mechanisms are 
uncertain. In this era of pandemic, a 
cardiologist should know the cardiac 
implication of COVID-19 and the use of 
ACEI and ARB in COVID-19 patients.
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